By a News Reporter-Staff News Editor at Biotech Week ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013, at
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito Bastianello Award for best abstract and oral presentation at the 12th International Symposium on...
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito Bastianello Award for best abstract and oral presentation at the 12th International Symposium on...
By a News Reporter-Staff News Editor at Biotech Week Toltec Pharmaceuticals, Llc has been issued patent application serial number 709740, according to news reporting originating out of Washington, D.C., by NewsRx editors. This patent application was filed on December 10, 2012 and was made available online on May 2, 2013. Unfortunately, national s
Location: Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services. Classification Code: B- Special studies and analysis- not R&D. Subject: Statistical Evaluation and Design, Conduct and Analysis of Clinical Studies for Therapeutic Biologic Products Regulated by CBER.
Dublin- Research and Markets has announced the addition of the "China Pharmaceutical Guidebook Series 3 2013 Edition- Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products" report to their offering. -A comprehensive and thorough..
Dublin- Research and Markets has announced the addition of the "China Pharmaceutical Guidebook Series 4 2013- Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines& Natural Medicines" report to their offering.
Robert Latta, R- Ohio, issued the following news release:. The House Energy and Commerce Committee today approved legislation introduced by Congressman Bob Latta that will strengthen and secure the nation's pharmaceutical distribution supply chain. Fred Upton, approved H.R. 1919, the Safeguarding America's Pharmaceuticals Act of 2013 by a voice vot
By a News Reporter-Staff News Editor at Biotech Week Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.
The FDA reviewed Xofigo under the agency's priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products. "Xofigo binds with minerals in the bone to deliver radiation directly
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. The U.S. Food and Drug Administration today approved a new use for Simponi injection to treat adults with moderate to severe ulcerative colitis. "Simponi is an important new treatment option for patients with moderate to severe ulcera
Basel Roche today announced that the U.S. Food and Drug Administration has approved Tarceva tablets for the initial treatment of people with metastatic non-small cell lung cancer whose tumours have certain epidermal growth factor receptor activating mutations as detected by a FDA approved test. The FDA also approved the cobas EGFR Mutation Test,
By a News Reporter-Staff News Editor at Biotech Week FORMA Therapeutics Holdings, LLC announced a strategic collaboration agreement with Celgene Corporation under which FORMA and Celgene will discover, develop and commercialize drug candidates to regulate protein homeostasis targets. The collaboration between FORMA and Celgene will be launched wi
NORTH-EAST patients may be the first in the UK to benefit from drug trials after a deal was signed between a hospital trust and a drug company. Prime Minister David Cameron, who is trying to encourage more research in UK hospitals, said he was delighted at the news. The Newcastle trust, which runs the Royal Victoria Infirmary and Freeman Hospital,
By a News Reporter-Staff News Editor at Biotech Week Ligand Pharmaceuticals Incorporated has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from Selexis SA. Geneva, Switzerland- based Selexis is a privately held global life science company focused on drug discovery for lead..
NeuroPhage Pharmaceuticals, Inc., a company developing therapies for neurodegenerative diseases, said that it raised $6.4 million in a private equity financing round. Separately, NeuroPhage announced that current Director John F. Dee has been named Chairman of the Board and Kenneth A. Buckfire has joined as a Director. Following a successful pre-IN
Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from TBI since 2010. This research published in the Journal BMC Neuroscience and available online finds; "The TBI induced cerebral ischemia, neurological motor deficits, and increased numbers of microglia-TNF-alpha double positive cells and increased...
Nimbus Discovery, a biotechnology company discovering novel medicines against previously inaccessible disease targets, has announced a co-development agreement with Shire plc focused on small molecule treatments for several rare genetic diseases known as lysosomal storage disorders. In a release, the Company said that the goal of the collaboration
By a News Reporter-Staff News Editor at Biotech Week Omeros Corporation announced that the European Medicines Agency has confirmed that the Company's planned Marketing Authorization Application for its ophthalmology product OMS302 can be submitted and reviewed under the EMA's centralized procedure. Omeros intends to submit a New Drug Application.
By a News Reporter-Staff News Editor at Biotech Week OncoGenex Pharmaceuticals, Inc. announced plans for the initiation of the Rainier? trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with ABRAXANE and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Release date- 14052013- San Mateo, California- Oracle has selected BioPharm Systems, a leading global IT consulting and managed services provider specializing in Oracle's clinical trial, data, safety, and pharmacovigilance management systems, to develop and deliver the Argus Safety Suite Implementation Boot Camp. Oracle's Enablement 2.0 Boot Camps
PharmaDirections has added another issued patent to their list of patents where they helped invent new technology for their clients. The patent is assigned to Orexigen Therapeutics, Inc. who currently has an NDA for Contrave under review at the FDA. Richard Soltero, President of PharmaDirections. This brings us to 21 issued and issued patents
SAN DIEGO, May 14, 2013 Receptos, Inc., a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the completion of its initial public offering of 5,200,000 shares of its common stock at an initial public offering price of $14. 00 per share. Receptos' common stock is listed o
The news correspondents obtained a quote from the research from Victoria Hospital, "Both medication and psychosocial interventions are recommended for the treatment of ADHD. In Europe, stimulants and atomoxetine are widely available medications for the treatment of ADHD, whereas in the US approved treatment options also include extended-release...
Basel- Roche today announced that important new data from clinical trials of several investigational and approved cancer medicines will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 to June 4, 2013, in Chicago. At the meeting, Roche medicines will be highlighted in more than 275 abstracts, of which aro
